# Ironwood Pharmaceuticals share price today (Ironwood Pharmaceuticals, Inc., IRWD)

> Ironwood Pharmaceuticals, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. IRWD · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/irwd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $3.50 (+82.3% in a year)
- P/E: 4.4× (lower than 92% of the last 4.6 years)
- Revenue (Jun 2026): $113 M (+32.6% on a year ago)
- Profit (Jun 2026): $51.3 M (+117.3% on a year ago)
- Operating margin: 70.2% (+17.3 points on a year ago)
- ROE: −9%, FY25
- ROIC: 65.7%, against a 5.3% cost of capital: +60.4 points
- Profit that came in as cash: 252%, last 3 years

The main question: yearly earnings per share moved +2,583.0% while the share price moved +82.3%. ## What is the Ironwood Pharmaceuticals share price today? Ironwood Pharmaceuticals, Inc.'s share price was $3.50 at the close on 3 November 2026. It has been moving sideways for 6 weeks. That is 12.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between $2 and $5, and at that close it sat 48% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 7 weeks running. Over the last 10 years the share price moved −74% while the S&P 500 moved +255%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Ironwood Pharmaceuticals pay? Ironwood Pharmaceuticals, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Ironwood Pharmaceuticals on? Ironwood Pharmaceuticals is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Ironwood Pharmaceuticals profitable? Ironwood Pharmaceuticals, Inc. earned $51.3 M of net profit in the Jun 2026 quarter, +117.3% on the same quarter a year earlier. Full-year FY25 profit was $24.0 M. Over 4 years profit has grown −53.8% a year on average. That is 45.4% of the quarter's revenue. The same quarter a year earlier earned $23.6 M. 5 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was $24.0 M (+2,629.2% on the year before). Why profit moved: revenue changed +32.6% on a year earlier and the margin moved +17.3 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +305.2% and revenue +44.4%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does Ironwood Pharmaceuticals make, and is it growing? Ironwood Pharmaceuticals, Inc. reported $113 M of revenue in the Jun 2026 quarter, +32.6% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown −8.0% a year on average. The last full year, FY25, came in at $296 M. The last four reported quarters add to $389 M. FY25 revenue was $296 M, −15.7% on the year before. Recent pace: the last four quarters grew +44.4% on average, against −8.0% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +26.2%, against −1.4% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Ironwood Pharmaceuticals keep? Ironwood Pharmaceuticals, Inc.'s operating margin was 70.2% in the Jun 2026 quarter, 17.3 percentage points higher than the same quarter a year ago. Across 5 years it has been between 27.4% and 61.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +17.3 percentage points on the year while gross margin changed +7.6 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Ironwood Pharmaceuticals' profit turning into cash? Over the last 3 years, 252% of Ironwood Pharmaceuticals, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $127 M of operating cash against $24.0 M of profit. After $34.0 K of spending on assets, $127 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Ironwood Pharmaceuticals' cash go? Ironwood Pharmaceuticals, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $449 K on assets over the last 3 years. Averaged over those years that is 0.1% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $449 K over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Ironwood Pharmaceuticals' P/E ratio, and how does it compare with its own history? Ironwood Pharmaceuticals, Inc.'s P/E is 4.4×, near the low end of its own history: it has been lower only 8% of the time. Its usual P/E (the middle reading) is 11.0×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +2,583.0% while the price moved +82.3%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved −28.3% a year; about −9.1% a year came from earnings growth and about −19.2 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Ironwood Pharmaceuticals business getting better or worse? Ironwood Pharmaceuticals, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Ironwood Pharmaceuticals earn on its capital? Ironwood Pharmaceuticals, Inc. earned a ROE of −9% in FY25. Its return on capital used (ROIC) is 60.4 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 8.1% net margin and 0.75× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 8.1% net margin × 0.75× asset turnover × −1.52× leverage (assets divided by equity) ≈ −9.2% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 65.7% − 5.3% = +60.4 percentage points. The 5.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 65.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 17.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Ironwood Pharmaceuticals have too much debt? Ironwood Pharmaceuticals, Inc.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from 0.79 in FY21 to −2.28 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Ironwood Pharmaceuticals shareholding pattern? 11.6% of Ironwood Pharmaceuticals, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 7.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Ironwood Pharmaceuticals from balance-sheet trouble? For Ironwood Pharmaceuticals, Inc., the Z-score is −2.34. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −2.34 is inside the danger zone, so the balance sheet is a real risk. ## How does Ironwood Pharmaceuticals rank in its industry? There is no score against its industry: Ironwood Pharmaceuticals, Inc. is not among the largest members shown in this industry comparison for Drug Manufacturers - Specialty & Generic. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Ironwood Pharmaceuticals compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Ironwood Pharmaceuticals in size? Ironwood Pharmaceuticals is the 36th largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Harrow, Inc., Esperion Therapeutics, Inc. and Collegium Pharmaceutical, Inc. Just below it: Evotec SE, Aquestive Therapeutics, Inc. and Evolus, Inc. ### Drug Manufacturers - Specialty & Generic companies close in size

1. [Harrow, Inc.](https://www.sectoralpha.in/us/stocks/hrow) $1.1 billion
2. [Esperion Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/espr) $819 million
3. [Collegium Pharmaceutical, Inc.](https://www.sectoralpha.in/us/stocks/coll) $773 million
4. Ironwood Pharmaceuticals, Inc. $578 million
5. [Evotec SE](https://www.sectoralpha.in/us/stocks/evo) $569 million
6. [Aquestive Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/aqst) $487 million
7. [Evolus, Inc.](https://www.sectoralpha.in/us/stocks/eols) $487 million

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [Vinci Compass Investments Ltd.](https://www.sectoralpha.in/us/stocks/vinp) $572 million · Asset Management
2. [Telesat Corporation](https://www.sectoralpha.in/us/stocks/tsat) $572 million · Communication Equipment
3. Ironwood Pharmaceuticals, Inc. $572 million
4. [Gilat Satellite Networks Ltd.](https://www.sectoralpha.in/us/stocks/gilt) $571 million · Communication Equipment
5. [Krispy Kreme, Inc.](https://www.sectoralpha.in/us/stocks/dnut) $568 million · Grocery Stores

## What else do people ask about Ironwood Pharmaceuticals? ### What were Ironwood Pharmaceuticals's latest quarterly results? Ironwood Pharmaceuticals, Inc. reported revenue of $113 M and net profit of $51.3 M for the Jun 2026 quarter. Revenue rose 32.6% and profit rose 117.3% compared with a year earlier. Earnings per share were $0.31. The operating margin was 70.2%, 17.3 percentage points higher than a year earlier (as of 3 November 2026). ### What is Ironwood Pharmaceuticals's market cap? Ironwood Pharmaceuticals, Inc.'s market capitalisation is $578 M at a stock price of $3.50. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Ironwood Pharmaceuticals performing? Ironwood Pharmaceuticals, Inc.'s share price has been moving sideways for 6 weeks. In its latest quarter, revenue rose 32.6% and profit rose 117.3% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 7 weeks running (as of 3 November 2026). ### Will Ironwood Pharmaceuticals's stock price go up? This page does not forecast Ironwood Pharmaceuticals, Inc.'s stock price. What it shows instead: the stock price is $3.50, and it has been moving sideways for 6 weeks. Its P/E of 4.4× is higher than 8% of its own last 5 years (as of 3 November 2026). ### Where is Ironwood Pharmaceuticals in its business cycle? Ironwood Pharmaceuticals, Inc.'s FY25 operating margin was 40.2%, against a 5-year range of 27.4% to 61.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 70.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Ironwood Pharmaceuticals story? The main question: yearly earnings per share moved +2,583.0% while the share price moved +82.3%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Ironwood Pharmaceuticals a stock worth studying right now? What the numbers show: Ironwood Pharmaceuticals, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.